These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 26608081)
1. Pharmacokinetics and Disposition of the Thiouracil Derivative PF-06282999, an Orally Bioavailable, Irreversible Inactivator of Myeloperoxidase Enzyme, Across Animals and Humans. Dong JQ; Varma MV; Wolford A; Ryder T; Di L; Feng B; Terra SG; Sagawa K; Kalgutkar AS Drug Metab Dispos; 2016 Feb; 44(2):209-19. PubMed ID: 26608081 [TBL] [Abstract][Full Text] [Related]
2. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Kalgutkar AS; Tugnait M; Zhu T; Kimoto E; Miao Z; Mascitti V; Yang X; Tan B; Walsky RL; Chupka J; Feng B; Robinson RP Drug Metab Dispos; 2011 Sep; 39(9):1609-19. PubMed ID: 21690265 [TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes. Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451 [TBL] [Abstract][Full Text] [Related]
4. Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome. Dong JQ; Gosset JR; Fahmi OA; Lin Z; Chabot JR; Terra SG; Le V; Chidsey K; Nouri P; Kim A; Buckbinder L; Kalgutkar AS Drug Metab Dispos; 2017 May; 45(5):501-511. PubMed ID: 28254951 [TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Kamath AV; Wang J; Lee FY; Marathe PH Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625 [TBL] [Abstract][Full Text] [Related]
6. Induction of human cytochrome P450 3A4 by the irreversible myeloperoxidase inactivator PF-06282999 is mediated by the pregnane X receptor. Moscovitz JE; Lin Z; Johnson N; Tu M; Goosen TC; Weng Y; Kalgutkar AS Xenobiotica; 2018 Jul; 48(7):647-655. PubMed ID: 28685622 [TBL] [Abstract][Full Text] [Related]
7. Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases. Ruggeri RB; Buckbinder L; Bagley SW; Carpino PA; Conn EL; Dowling MS; Fernando DP; Jiao W; Kung DW; Orr ST; Qi Y; Rocke BN; Smith A; Warmus JS; Zhang Y; Bowles D; Widlicka DW; Eng H; Ryder T; Sharma R; Wolford A; Okerberg C; Walters K; Maurer TS; Zhang Y; Bonin PD; Spath SN; Xing G; Hepworth D; Ahn K; Kalgutkar AS J Med Chem; 2015 Nov; 58(21):8513-28. PubMed ID: 26509551 [TBL] [Abstract][Full Text] [Related]
8. Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. Eng H; Sharma R; Wolford A; Di L; Ruggeri RB; Buckbinder L; Conn EL; Dalvie DK; Kalgutkar AS Drug Metab Dispos; 2016 Aug; 44(8):1262-9. PubMed ID: 27079250 [TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist. Bungay PJ; Tweedy S; Howe DC; Gibson KR; Jones HM; Mount NM Drug Metab Dispos; 2011 Aug; 39(8):1396-405. PubMed ID: 21543556 [TBL] [Abstract][Full Text] [Related]
10. Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species. Kalgutkar AS; Choo E; Taylor TJ; Marfat A Xenobiotica; 2004 Aug; 34(8):755-70. PubMed ID: 15690763 [TBL] [Abstract][Full Text] [Related]
11. Metabolism and pharmacokinetics characterization of metarrestin in multiple species. Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484 [TBL] [Abstract][Full Text] [Related]
12. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human. Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022 [TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetics and oral bioavailability of BMS-310705, a novel epothilone B analog. Kamath AV; Chang M; Lee FY; Zhang Y; Marathe PH Cancer Chemother Pharmacol; 2005 Aug; 56(2):145-53. PubMed ID: 15830240 [TBL] [Abstract][Full Text] [Related]
15. The Nonclinical Pharmacokinetics and Prediction of Human Pharmacokinetics of SPH3127, a Novel Direct Renin Inhibitor. Zhang L; Mao Y; Gao Z; Chen X; Li X; Liu Y; Xia G Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):15-26. PubMed ID: 31494843 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and elucidation of the rates and routes of N-glucuronidation of PF-592379, an oral dopamine 3 agonist in rat, dog, and human. Attkins N; Betts A; Hepworth D; Heatherington AC Xenobiotica; 2010 Nov; 40(11):730-42. PubMed ID: 20836725 [TBL] [Abstract][Full Text] [Related]
17. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human. Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419 [TBL] [Abstract][Full Text] [Related]
18. In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis. Mukkavilli R; Pinjari J; Patel B; Sengottuvelan S; Mondal S; Gadekar A; Verma M; Patel J; Pothuri L; Chandrashekar G; Koiram P; Harisudhan T; Moinuddin A; Launay D; Vachharajani N; Ramanathan V; Martin D Eur J Pharm Sci; 2014 Dec; 65():147-55. PubMed ID: 25261338 [TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Gu Y; Wang J; Li K; Zhang L; Ren H; Guo L; Sai Y; Zhang W; Su W Cancer Chemother Pharmacol; 2014 Jul; 74(1):95-115. PubMed ID: 24817647 [TBL] [Abstract][Full Text] [Related]
20. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Obermeier M; Yao M; Khanna A; Koplowitz B; Zhu M; Li W; Komoroski B; Kasichayanula S; Discenza L; Washburn W; Meng W; Ellsworth BA; Whaley JM; Humphreys WG Drug Metab Dispos; 2010 Mar; 38(3):405-14. PubMed ID: 19996149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]